Regeneron says its antibody cocktail likely weakened by Omicron variant

Regeneron says its antibody cocktail likely weakened by omicron variant

(HealthDay)—Regeneron Pharmaceuticals said Tuesday that its antibody cocktail, which is used widely to treat COVID-19 patients, may be less effective against the Omicron variant.

The noted that prior analyses suggest that its monoclonal antibody cocktail, and similar drugs, could lose effectiveness against the variant.

Further research is ongoing, according to Regeneron, which added there is no direct data yet testing the new variant's resistance to immunity from monoclonal antibodies and vaccines. The company did note that it is already testing the next generation of antibody treatments that might show greater potency against the Omicron variant.

Health officials consider highly effective in preventing hospitalization among patients with mild to moderate COVID-19 if the therapy is given within seven to 10 days after symptoms appear.

The treatment—typically administered through four injections or a half-hour infusion—provides antibodies that quickly target the coronavirus while the body's immune system gears up to fight it, the Washington Post reported.

President Donald Trump was given Regeneron's antibody cocktail when he was infected with the virus in 2020. It is now widely available to the American public.


Explore further

Antibody cocktail offers much-needed COVID-19 protection

More information: Visit the U.S. National Institutes of Health for more on COVID antibody treatments.

Copyright © 2021 HealthDay. All rights reserved.

Citation: Regeneron says its antibody cocktail likely weakened by Omicron variant (2021, November 30) retrieved 18 January 2022 from https://medicalxpress.com/news/2021-11-regeneron-antibody-cocktail-weakened-omicron.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors